FGF21 and obesity due to melanocortin 4 receptor deficiency: Given the promising therapeutic efficacy against obesity and type 2 diabetes in preclinical studies, several FGF21 analogues and mimetics have been developed as pharmacological intervention strategies and are currently undergoing several clinical trials in patients with obesity, type 2 diabetes, and NASH [115,190,191,192,193].